This Viewpoint supports Sustainable Development Goal 3 by discussing the effects of the FDA's approval of aducanumab, a treatment for early-stage Alzheimer's disease, despite its limited clinical benefit, as well as the decision of the Centers for Medicare and Medicaid Services to restrict coverage to individuals enrolled in clinical trials. The authors note that these decisions have led to a confusing landscape for patients with Alzheimer's disease.